Abstract:Objective: To detect the expression of miR-221/222 in serum and plasma cells in patients with monoclonal gammopathy of undetermined significance(MGUS) and multiple myeloma(MM), and to explore the possibility of miR-221/222 as biomarkers in the diagnosis and prognosis predicting of MGUS and MM. Methods: Bone marrow and serum samples from 14 patients with newly diagnosed MGUS, 81 patients with newly diagnosed or relapsed MM and 10 controls were collected from Sir Run Run Shaw Hospital of Zhejiang University and Tongde Hospital of Zhejiang Province during January 2013 and December 2015. The expressions of miR-221/222 in serum and in sorted CD138 positive plasma cells were detected by qRT-PCR, and the relative expression of miR-221/222 (Δct) was compared between the groups. Serum levels of miR-221 before and after treatment were compared in both remission group (n=22) and refractory group (n=13) in MM patients, and its correlation with serum level of β2-MG was assessed using Pearson's correlation analysis. Results: Serum levels of miR-221/222 in MGUS and MM groups were significantly higher than those in control group (all P<0.01), while miR-221/222 levels in plasma cells were significantly lower in MGUS and MM groups than those in the control group (P<0.05 or<0.01). No significant difference in miR-221/222 levels in serum and plasma cells was observed between MGUS group and MM group (all P>0.05). There was no correlation between miR-221/222 levels in serum and plasma cells (r=0.024 and -0.127, all P>0.05), but miR-221 levels were correlated with miR-222 levels in both serum and plasma cells (r=0.534 and 0.552, all P<0.01). Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) of serum miR-221/222, plasma cell miR-221/222 in diagnosis of MGUS/MM were 0.968, 0.976, 0.801 and 0.727, respectively. There was no significant difference in serum level of miR-221 among MM patients with different paraprotein isotypes (P>0.05), but serum level of miR-221 in patients with relapsed MM was higher than that in patients with newly diagnosed MM (P<0.01). Compared with the patients with MGUS or MM stageⅠ and Ⅱ, patients with MM stage Ⅲ were of higher serum levels of miR-221 (P<0.01). Serum level of miR-221 decreased after chemotherapy in the remission group (U=51.5, P<0.01), but such decrease was not observed in the refractory group (U=67.5, P>0.05). Serum level of β2-MG was positively correlated with serum level of miR-221 (r=0.524, P<0.01). Conclusion: miR-221/222 in serum and plasma cells may be biomarkers for early diagnosis of MGUS, and are helpful for diagnosis and efficacy evaluation of MM.

[Study on the Diagnostic Significance of Detecting the Expression of AChR-gamma Mrna in Rhabdomyosarcoma Tissues].

Quantitative detection of AMACR mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) and the clinical significance

[Expression of Microrna-221/222 in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma].

[Detection of PAX3/PAX7-FKHR Fusion Transcript in Rhabdomyosarcoma by One-Step RT-PCR].

[Diagnostic Significance and Clinical Application of Specific Chimeric Genes in Soft Tissue Sarcomas by RT-PCR Using Paraffin-Embedded Tissues: a Study of 103 Specimens].

[The Relation Between Reg 1A Mrna Expression and the Clinicopathologic Parameters in the Patients with Primary Gastric Carcinoma].

Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]

Increased DNA Methyltransferase Expression in Rhabdomyosarcomas

Detection of RASSF1A Mrna in Glioma Using SYBR Green Ⅰ Quantitative Real-time PCR

Serum tRF-27-FDXXE6XRK45 as a Promising Biomarker for the Clinical Diagnosis in Gastric Cancer

Detection of Myogenin Protein of Rhabdomyosarcomas in Children: Gene Expression and Diagnostic Experiment

Expression and Clinical Contribution of Mrgd Mrna in Non-Small Cell Lung Cancers

Expressions of MAGE-A 3, MAGE-A 6 and MAGE-A 10 genes in peripheral blood of patients with colorectal carcinoma and their clinical signi cance

[Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas]

Expression and Significance of Myogenic Factors in 32 Children with Rhbdomyosarcoma

Chromosomal And Genetic Imbalances In Chinese Patients With Rhabdomyosarcoma Detected By High-Resolution Array Comparative Genomic Hybridization

Expression of RhoA and RhoC in Colorectal Carcinoma and Its Relations with Clinicopathological Parameters.

CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis

Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease

EVALUATION OF IMMUNOHISTOCHEMICAL DIAGNOSIS OF RHABDOMYOSARCOMA

Clinical Application of Clustered-Achr for the Detection of SNMG.